Related Experiment Video
Updated: Mar 21, 2026
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell
Kyu-Tae Kim1, Hye Won Lee2, Hae-Ock Lee1,3
1Samsung Genome Institute, Samsung Medical Center, Seoul, South Korea.
Background:
Intratumoral heterogeneity hampers the success of marker-based anticancer treatment because the targeted therapy may eliminate a specific subpopulation of tumor cells while leaving others unharmed. Accordingly, a rational strategy minimizing survival of the drug-resistant subpopulation is essential to achieve long-term therapeutic efficacy.
Results:
Using single-cell RNA sequencing (RNA-seq), we examine the intratumoral heterogeneity of a pair of primary renal cell carcinoma and its lung metastasis. Activation of drug target pathways demonstrates considerable variability between the primary and metastatic sites, as well as among individual cancer cells within each site. Based on the prediction of multiple drug target pathway activation, we derive a combinatorial regimen co-targeting two mutually exclusive pathways for the metastatic cancer cells. This combinatorial strategy shows significant increase in the treatment efficacy over monotherapy in the experimental validation using patient-derived xenograft platforms in vitro and in vivo.
Conclusions:
Our findings demonstrate the investigational application of single-cell RNA-seq in the design of an anticancer regimen. The approach may overcome intratumoral heterogeneity which hampers the success of precision medicine.
Insights
Single-cell RNA sequencing revealed significant variability in cancer cell drug targets. A combination therapy targeting two pathways effectively treated metastatic cancer, overcoming treatment resistance.
Area of Science:
- Oncology
- Genomics
- Translational Medicine
Background:
- Intratumoral heterogeneity poses a major challenge to effective anticancer therapies.
- Targeted treatments often fail due to the survival of drug-resistant cancer cell subpopulations.
- Developing strategies to overcome resistance is crucial for long-term therapeutic success.
Purpose of the Study:
- To investigate intratumoral heterogeneity using single-cell RNA sequencing.
- To design a combinatorial anticancer regimen that addresses drug resistance.
- To evaluate the efficacy of the novel regimen in preclinical models.
Main Methods:
- Single-cell RNA sequencing (RNA-seq) was employed to analyze primary and metastatic renal cell carcinoma.
- Drug target pathway activation variability was assessed within and between tumor sites.
- A combinatorial regimen targeting two mutually exclusive pathways was designed based on RNA-seq predictions.
Main Results:
- Significant variability in drug target pathway activation was observed among individual cancer cells and between primary and metastatic sites.
- The combinatorial regimen demonstrated superior efficacy compared to monotherapy.
- Preclinical validation in patient-derived xenograft models confirmed the enhanced treatment effect in vitro and in vivo.
Conclusions:
- Single-cell RNA sequencing can be utilized to design effective anticancer regimens.
- This approach offers a potential strategy to overcome intratumoral heterogeneity in precision medicine.
- The findings support the development of combination therapies tailored to individual tumor profiles.
More Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...